BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 8, Issue 8
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©The Author(s) 2020.
World J Clin Cases. Apr 26, 2020; 8(8): 1361-1384
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1361
Table 6 Trials assessing the effect of VSL#3 in patients with cirrhosis
Ref.DesignnVSL#3 intake
Gupta et al[127], 2013RCT94 with cirrhosis2 mo with 9 × 1011 CFU a day
Jayakumar et al[129], 2013RCT17 with decompensated cirrhosis; 15 completed2 mo with 3.6 × 1012 bacteria a day
Rincón et al[128], 2014Not mentioned17 with cirrhosis and ascites; 12 completed6 wk, the dose was not clear
Marlicz et al[130], 2016Not mentioned20 with cirrhosis (13 with compensated liver cirrhosis, 7 with decompensated liver cirrhosis), and 10 healthy controlsDaily for 28 d, the daily dose was not clear
RCT: Randomized controlled trial; CFU: Colony-forming unit.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.